Acute negative inotropic effects of homocysteine are mediated via the endothelium

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 287, Issue 2 56-2, 2004, Pages

  Kennedy, Richard H ^a,b   Owings, Richard ^a   Shekhawat, Nawal ^b   Joseph, Jacob ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Contractility; Langendorff perfused heart; Papillary muscle; Rat; Triton X 100 treatment

Indexed keywords

BUFFER; HOMOCYSTEINE; INDOMETACIN; N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; TRITON X 100;

ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DISEASE ASSOCIATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE PERFUSION; HEART PAPILLARY MUSCLE; HEART VENTRICLE REMODELING; HYPERHOMOCYSTEINEMIA; INOTROPISM; ISOLATED HEART; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PARACRINE SIGNALING; PARAMETER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SYSTOLE; TISSUE STRUCTURE;

ANIMALS; CARDIOVASCULAR AGENTS; CORONARY VESSELS; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HEART; HOMOCYSTEINE; INDOMETHACIN; MALE; MYOCARDIAL CONTRACTION; NITROARGININE; OCTOXYNOL; PAPILLARY MUSCLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 3242734851     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01042.2003     Document Type: Article

References (33)

1. Arnold G, Kosche F, Miessner E, Neitzert A, and Lochner W. The importance of perfusion pressure in the coronary arteries for the contractility and the oxygen consumption of the heart. Pflügers Arch 299: 339-356, 1968.
2. Blacher J, Demuth K, Guerin AP, Vadez C, Moatti N, Safar ME, and London GM. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol 12: 248-255, 1999.
3. Boushey CJ, Beresford SA, Omenn GS, and Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. JAMA 274: 1049-1057, 1995.
4. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance and rhythmicity. Physiol Rev 83: 59-115, 2002.
5. 4: effects on human and guinea-pig cardiac preparations in vitro. J Pharmacol Exp Ther 221: 235-241, 1982,
6. Chwatki G and Bald E. Determination of different species of homocysteine in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr A 949: 141-151, 2002.
7. Dijkman MA, Heslinga JW, Sipkema P, and Westerhof N. Perfusion-induced changes in cardiac contractility depend on capillary perfusion. Am J Physiol Heart Circ Physiol 274: H405-H410, 1998.
8. Downey JM. Myocardial contractile function as a function of coronary blood flow. Am J Physiol 230: 1-6, 1976.
9. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, and Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 106: 483-491, 2000.
10. Gregg, DE. Effect of coronary perfusion pressure or coronary flow on oxygen usage of the myocardium. Circ Res 13: 497-500, 1963.
11. Joseph J, Joseph L, Shekhawat NS, Devi S, Wang J, Melchert RB, Hauer-Jensen M, and Kennedy RH. Hyperhomocysteinemia leads to pathologic ventricular hypertrophy in normotensive rats. Am J Physiol Heart Circ Physiol 285: H679-H686, 2003.
12. Joseph J, Washington A, Joseph L, Koehler L, Fink LM, Hauer-Jensen M, and Kennedy RH. Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol 283: H2567-H2574, 2002.
13. Karmazyn M, Leung CKH, and Dhalla NS. Prostaglandin actions and interactions on isolated perfused rat hearts. Can J Physiol Pharmacol 57: 1275-1282, 1979.
14. Li K, Rouleau JL, Andries LJ, and Brutsaert DL. Effect of dysfunctional vascular endothelium on myocardial performance in isolated papillary muscles. Circ Res 72: 768-777, 1993.
15. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 98: 5-7, 1996.
16. McCully KS. Vascular pathology of hyperhomocysteinemia: implications for the development of arteriosclerosis. Am J Pathol 56: 111-128, 1969.
17. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, and Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337: 230-236, 1997.
18. Nygard O, Vollset SE, Refsum H, Brattstrom L, and Ueland PM. Total homocysteine and cardiovascular disease. J Intern Med 246: 425-454, 1999.
19. Pratt PF, Nithipatikom K, and Campbell WB. Simultaneous determination of nitrate and nitrite in biological samples by multiflow injection analysis. Anal Biochem 231: 383-386, 1995.
20. Ramaciotti C, McClellan G, Sharkey A, Rose D, Weisberg A, and Winegrad S. Cardiac endothelial cells modulate contractility of rat heart in response to oxygen tension and coronary flow. Circ Res 72: 1044-1064, 1993.
21. Schnyder G, Orf M, Pin R, Flapper Y, Lange H, Eberle FR, Meier B, Tru SG, and Hess OM. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345: 1593-1600, 2001.
22. + currents by homocysteine in rat ventricular myocytes. J Cardiovasc Electrophysiol 12: 175-182, 2001.
23. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, and Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91: 308-318, 1993.
24. +-ATPase activity caused by homocysteine. Int J Dev Neurosci 20: 77-81, 2002.
25. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, and Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104: 2569-2575, 2001.
26. Szekeres L, Borbola J Jr, and Papp JG. Cardiac actions of arachidonic acid. Acta Biol Med Ger 35: 1119-1126, 1976.
27. Tyagi SC, Smiley LM, and Mujumdar VS. Homocyst(e)ine impairs endocardial endothelial function. Can J Physiol Pharmacol 77: 950-957, 1999.
28. i and constrictor responses of isolated arterioles. J Cardiovasc Pharmacol 37: 705-712, 2001.
29. Upchurch GR, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF, and Loscalzo J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272: 17012-17017, 1997.
30. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Rosenberg IH, and Wilson PWF. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 289: 1251-1257, 2003.
31. Wang S, Wright G, Harrah J, Touchon R, McCumbee W, Geng W, Fultz ME, Abdul-Jalil MN, and Wright GL. Short-term exposure to homocysteine depresses rat aortic contractility by an endothelium-dependent mechanism. Can J Physiol Pharmacol 78: 500-506, 1999.
32. Weiss N, Zhang YY, Heydrick S, Bierl C, and Loscalzo J. Overexpression of cellular glutathione peroxidase rescues homocysteine-induced endothelial dysfunction. Proc Natl Acad Sci USA 98: 12503-12508, 2001.
33. Zheng H, Dimayuga C, Hudaihed A, and Katz SD. Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. Arterioscler Thromb Vasc Biol 22: E15-E18, 2002.